Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Red Cat Holdings, Inc. due to allegations of misleading statements regarding the company's production capacity and contract values, which have led to significant stock price declines for investors [2][4][12]. Group 1: Allegations and Legal Actions - The complaint alleges that Red Cat and its executives violated federal securities laws by making false and misleading statements about the production capacity of the Salt Lake City Facility and the overall value of the SRR Contract [4][6]. - Investors who suffered losses from purchasing Red Cat securities between March 18, 2022, and January 15, 2025, are encouraged to discuss their legal rights with Faruqi & Faruqi [1][2]. - A federal securities class action has been filed against Red Cat, with a deadline of July 21, 2025, for investors to seek the role of lead plaintiff [2][14]. Group 2: Company Performance and Stock Impact - Red Cat's stock price fell by $0.10 per share (8.93%) to close at $1.02 on July 28, 2023, following disclosures about the actual production capacity of the Salt Lake City Facility being only 100 drones per month [8][7]. - On September 25, 2024, Red Cat's stock price dropped by $0.80 per share (25.32%) after the company reported losses per share of $0.17 and revenue of $2.8 million, missing consensus estimates [10][9]. - After Kerrisdale Capital published a report on January 16, 2025, alleging that the SRR Contract was worth only $20 million to $25 million, Red Cat's stock price fell by $2.35 per share (21.54%) to close at $8.56 on January 17, 2025 [12][13]. Group 3: Company Background and Initiatives - Red Cat was selected by the U.S. Department of Defense's Defense Innovation Unit to compete in the SRR Program, aimed at providing small, portable sUAS to U.S. Army platoons [5]. - The company has claimed that the SRR Contract could potentially generate hundreds of millions in revenue, with expectations of $50 million to $79.5 million in revenue during fiscal year 2025 [11].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BigBear.ai Holdings, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading financial statements and accounting practices [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that BigBear maintained deficient accounting review policies, leading to incorrect determinations regarding the 2026 Convertible Notes and improper accounting practices [4]. - As a result of these errors, BigBear's financial statements since fiscal year 2021 are deemed unreliable and will require restatement, increasing the risk of delayed filings with the SEC [4][6]. - Following the announcement of the delayed filing of its 2024 10-K, BigBear's stock price fell approximately 15%, from $3.49 on March 17, 2025, to $2.97 on March 18, 2025 [5]. - After the filing of the restated 2024 10-K, the stock price declined further by about 9%, from $3.51 on March 25, 2025, to $3.19 on March 26, 2025 [7]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses in BigBear.ai between March 31, 2022, and March 25, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1]. - There is a June 10, 2025, deadline for investors to seek the role of lead plaintiff in the federal securities class action against BigBear [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Open Lending Corporation due to alleged violations of federal securities laws, encouraging affected investors to come forward before the June 30, 2025 deadline for lead plaintiff applications in a class action lawsuit [2][4]. Group 1: Allegations Against Open Lending - The complaint alleges that Open Lending and its executives made false or misleading statements and failed to disclose material adverse facts about the company's business and operations [4]. - Specific allegations include misrepresentation of the company's risk-based pricing models, misleading statements regarding profit share revenue, and failure to disclose the significant depreciation of 2021 and 2022 vintage loans [4]. - The complaint also claims that the company misrepresented the underperformance of its 2023 and 2024 vintage loans, leading to materially misleading positive statements about its business prospects [4]. Group 2: Stock Price Impact - On March 17, 2025, Open Lending postponed its earnings release and conference call, resulting in a stock price drop of $0.40, or 9.3%, closing at $3.91 per share [5]. - Following the announcement of a substantial year-over-year increase in net loss for Q4 2024 and significant leadership changes on March 31, 2025, the stock price plummeted by $1.59, or 57.61%, closing at $1.17 per share on April 1, 2025 [6]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is also adequate and typical of class members, overseeing the litigation on behalf of the class [7]. - Any member of the putative class can move to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [7].

PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION What happened: The filed complaint alleges that throughout the Class Period, the defendants made materially false, misleading and potentially damaging statements regarding the Business Operations of Bitfarms. On May 9, 2025, a complaint was filed against the Company and certain of its current and former officers, alleging that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: Why W ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Avis To Contact Him Directly To Discuss Their Options NEW YORK, May 7, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Avis Budget Group, Inc. ("Avis" or the "Company") (NASDAQ: CAR) and reminds investors of the June 24, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SoundHound AI, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by May 27, 2025 [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in SoundHound AI between May 10, 2024, and March 3, 2025, to discuss their legal options [1]. - The complaint alleges that SoundHound and its executives made false and misleading statements regarding the company's internal controls and financial reporting, particularly related to corporate acquisitions [4]. - SoundHound disclosed on March 4, 2025, that it would be unable to timely file its Annual Report for 2024 due to complexities in accounting for acquisitions, leading to a 5.81% drop in stock price [5]. Group 2: Company Background and Context - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding SoundHound's conduct [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Actinium Pharmaceuticals, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's Iomab-B BLA application and its clinical trial data [2][4]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses exceeding $75,000 in Actinium between October 31, 2022, and August 2, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against Actinium, with a deadline of May 26, 2025, for investors to seek the role of lead plaintiff [2][6]. Group 2: Allegations Against Actinium - The complaint alleges that Actinium and its executives made false and misleading statements regarding the likelihood of FDA approval for the Iomab-B BLA, based on data from the Sierra Trial [4]. - It is claimed that the additional analyses provided to the FDA were unlikely to satisfy the agency's guidelines, leading to a probable refusal to review or approve the BLA [4]. Group 3: Impact on Stock Price - Following the revelation of the need for an additional clinical trial to support the BLA filing, Actinium's stock price dropped significantly, falling $3.69, or nearly 60%, to close at $2.48 on August 5, 2024 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against The Bancorp, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by May 16, 2025 [3][11]. Group 1: Allegations Against The Bancorp - The complaint alleges that The Bancorp and its executives made false or misleading statements regarding the risks associated with its REBL loan portfolio, including underrepresenting the risk of default [5]. - It is claimed that the company's expected credit loss methodology was inadequate, leading to a likely increase in provisions for credit losses [5]. - The company reportedly had material weaknesses in its internal controls over financial reporting, and its financial statements were not approved by independent auditors, making them unreliable [5]. Group 2: Market Reactions and Financial Disclosures - Following a report from Culper Research on March 21, 2024, alleging significant risks in the company's loan portfolio, The Bancorp's share price fell by $3.63, or 10.15%, closing at $32.12 [7]. - On October 24, 2024, the company reported a net income of $51.5 million for Q3 2024, but this included a $1.5 million reduction due to increased provisions for credit losses, leading to a share price drop of $7.95, or 14.47%, to $47.01 [8]. - On March 4, 2025, The Bancorp disclosed that its financial statements for fiscal years 2022 to 2024 should no longer be relied upon, resulting in a share price decline of $2.34, or 4.38%, to $51.25 [9][10].

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for alleged violations of federal securities laws, particularly concerning misleading statements and undisclosed material facts related to Cerevel's stock offerings and acquisition processes [6][4][7]. Group 1: Legal Allegations - The complaint alleges that the defendants made false and/or misleading statements and failed to disclose material facts during Cerevel's secondary stock offering on October 16, 2023, where shares were sold at $22.81 [6]. - Bain Capital is accused of acquiring Cerevel shares while allegedly possessing nonpublic information about AbbVie's interest in acquiring the company, which was later disclosed at a price of $45 per share [6][7]. - The January 18, 2024, Proxy statement regarding the AbbVie acquisition is claimed to have misled investors about the sales process and conflicts of interest, suggesting that Bain and Pfizer orchestrated the process to maximize profits at the expense of public shareholders [6][7]. Group 2: Class Action Details - Investors who sold or disposed of Cerevel stock between October 11, 2023, and August 1, 2024, or held shares as of January 8, 2024, may have been damaged by the defendants' actions and are encouraged to contact the law firm for legal options [1][4]. - The deadline for investors to seek the role of lead plaintiff in the federal securities class action is June 3, 2025 [4]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [8].

Core Insights - Holzer & Holzer, LLC is investigating TechTarget, Inc. for potential non-compliance with federal securities laws following the announcement of accounting errors in previously issued financial statements [1] - The announcement led to a decline in TechTarget's stock price [1] Company Summary - TechTarget, Inc. is facing scrutiny due to accounting errors related to the Informa Tech Digital Businesses of Informa PLC, which has raised concerns about the reliability of its financial statements [1] - The investigation by Holzer & Holzer, LLC indicates potential legal implications for TechTarget and its shareholders [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in cases of corporate misconduct [3] - The firm has a history of recovering significant amounts for shareholders affected by fraud, indicating a proactive approach to investor rights [3]